Wedbush Initiates Coverage On Mentari Therapeutics with Outperform Rating, Announces Price Target of $33

Benzinga · 22h ago
Wedbush analyst Laura Chico initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Outperform rating and announces Price Target of $33.